CRBP
Price
$3.88
Change
-$0.03 (-0.77%)
Updated
Nov 3, 04:59 PM (EDT)
Capitalization
75.72M
8 days until earnings call
Intraday BUY SELL Signals
DYN
Price
$17.87
Change
+$0.57 (+3.29%)
Updated
Nov 3, 03:57 PM (EDT)
Capitalization
3.23B
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRBP vs DYN

CRBP vs DYN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CRBP vs. DYN commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBP is a StrongBuy and DYN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CRBP with price predictions
Nov 02, 2026

CRBP's Stochastic Oscillator slumps into oversold zone

The Stochastic Oscillator for CRBP moved into oversold territory on November 02, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for CRBP just turned positive on October 22, 2026. Looking at past instances where CRBP's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.

Following a +6.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBP advanced for three days, in 228 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The 50-day moving average for CRBP moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for CRBP entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.741) is normal, around the industry mean (3.104). P/E Ratio (-0.641) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for DYN with price predictions
Nov 02, 2026

DYN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for DYN turned positive on October 01, 2026. Looking at past instances where DYN's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DYN's RSI Oscillator exited the oversold zone, 28 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on DYN as a result. In 63 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

Following a +0.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where DYN advanced for three days, in 239 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

DYN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for DYN moved below the 200-day moving average on October 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DYN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for DYN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.601) is normal, around the industry mean (3.104). P/E Ratio (-5.307) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. DYN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DYN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
CRBP vs DYN: Fundamental Ratings
CRBP
DYN
OUTLOOK RATING
1..100
5336
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
10097
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
9262
P/E GROWTH RATING
1..100
919
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DYN's Valuation (52) in the Electric Utilities industry is in the same range as CRBP (63) in the Biotechnology industry. This means that DYN’s stock grew similarly to CRBP’s over the last 12 months.

DYN's Profit vs Risk Rating (97) in the Electric Utilities industry is in the same range as CRBP (100) in the Biotechnology industry. This means that DYN’s stock grew similarly to CRBP’s over the last 12 months.

DYN's SMR Rating (98) in the Electric Utilities industry is in the same range as CRBP (98) in the Biotechnology industry. This means that DYN’s stock grew similarly to CRBP’s over the last 12 months.

DYN's Price Growth Rating (62) in the Electric Utilities industry is in the same range as CRBP (92) in the Biotechnology industry. This means that DYN’s stock grew similarly to CRBP’s over the last 12 months.

CRBP's P/E Growth Rating (9) in the Biotechnology industry is in the same range as DYN (19) in the Electric Utilities industry. This means that CRBP’s stock grew similarly to DYN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRBPDYN
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 6 days ago
84%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 12 days ago
86%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (CRBP: $3.91 vs. DYN: $17.30)
Brand notoriety: CRBP and DYN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBP: 66% vs. DYN: 85%
Market capitalization -- CRBP: $75.72M vs. DYN: $3.23B
CRBP [@Biotechnology] is valued at $75.72M. DYN’s [@Biotechnology] market capitalization is $3.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $140.2B. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBP’s FA Score shows that 1 FA rating(s) are green while DYN’s FA Score has 1 green FA rating(s).

  • CRBP’s FA Score: 1 green, 4 red.
  • DYN’s FA Score: 1 green, 4 red.
According to our system of comparison, DYN is a better buy in the long-term than CRBP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBP’s TA Score shows that 3 TA indicator(s) are bullish while DYN’s TA Score has 5 bullish TA indicator(s).

  • CRBP’s TA Score: 3 bullish, 3 bearish.
  • DYN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DYN is a better buy in the short-term than CRBP.

Price Growth

CRBP (@Biotechnology) experienced а -1.88% price change this week, while DYN (@Biotechnology) price change was +10.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.06%. For the same industry, the average monthly price growth was -12.02%, and the average quarterly price growth was -17.00%.

Reported Earning Dates

CRBP is expected to report earnings on Nov 11, 2026.

DYN is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CRBP
Daily Signal:
Gain/Loss:
DYN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
+3.65%
RNA - DYN
64%
Loosely correlated
+3.39%
SLDB - DYN
49%
Loosely correlated
-3.23%
XNCR - DYN
49%
Loosely correlated
-0.54%
KURA - DYN
49%
Loosely correlated
-4.58%
CLDX - DYN
49%
Loosely correlated
-3.52%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TSXD6.270.28
+4.67%
Direxion Daily Semiconductors Top 5 Bear 2X ETF (TSXD)
PLTD4.950.15
+3.12%
Direxion Dailly PLTR Bear 1X ETF (PLTD)
FLQM62.120.70
+1.14%
Franklin U.S. Mid Cap Multifactor Index ETF (FLQM)
UIVM73.580.20
+0.27%
VictoryShares International Value Momentum ETF (UIVM)
PIFI91.70N/A
N/A
ClearShares Piton Intermediate Fixed Income ETF (PIFI)